Developing and validating SIM-2: the first therapeutic vaccine for Genital Herpes
| Reference number | |
| Coordinator | Simplexia AB |
| Funding from Vinnova | SEK 3 663 396 |
| Project duration | November 2024 - November 2026 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
The HERVAX project aims to develop a new genital herpes (HSV-2) vaccine, for clinical trials. SIM-2 uses Simplexia´s patented technology to develop the gG2-EXCT4 antigen that will elicit an HSV-2-specific immune response, stopping disease progression and transmissibility of the virus. This will be the first therapeutic vaccine against HSV-2.
Expected effects and result
A candidate vaccine against genital herpes caused av Herpes simplex virus-2.
Planned approach and implementation
Analytical Method Development Microparticle and microneedle development and screening Adjuvant screening with VFI candidate Analytical Method Development gG-2 EXCT4 microspheres Dosing strategy identified using Mouse Challenge Model for HSV-2 Preclinical human in vitro efficacy studies